Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Change in injecting behaviour among people treated for hepatitis C virus: The role of intimate partnerships.

Malaguti A, Sani F, Stephens BP, Ahmad F, Dugard P, Dillon JF; ERADICATE-C Study Group.

J Viral Hepat. 2019 Jan;26(1):65-72. doi: 10.1111/jvh.13009. Epub 2018 Oct 25.

PMID:
30260560
2.

Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.

Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop A, Foster GR, Hellard M, Robaeys G, Thurnheer MC, Weltman M, Amin J, Marks PS, Quiene S, Dore GJ, Dalgard O, Grebely J; ACTIVATE Study Group.

Int J Drug Policy. 2017 Sep;47:230-238. doi: 10.1016/j.drugpo.2017.05.040. Epub 2017 Jun 19.

PMID:
28633998
3.

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.

Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Amin J, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Hellard M, Bruneau J, Midgard H, Bourgeois S, Staehelin C, Dore GJ; ACTIVATE Study Group.

Int J Drug Policy. 2017 Sep;47:177-186. doi: 10.1016/j.drugpo.2017.05.020. Epub 2017 Jun 16.

PMID:
28624134
4.

Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.

Grebely J, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, Phung N, Weltman MD, Day CA, Treloar C, Bath N, Haber PS, Dore GJ; ETHOS Study Group.

Addiction. 2016 Feb;111(2):311-9. doi: 10.1111/add.13197. Epub 2015 Nov 25.

PMID:
26451534
5.

The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.

Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, May M, Taylor A, De Angelis D, Cameron S, Parry J, Lyons M, Goldberg D, Allen E, Hickman M.

Addiction. 2011 Nov;106(11):1978-88. doi: 10.1111/j.1360-0443.2011.03515.x. Epub 2011 Aug 24.

PMID:
21615585
6.

Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.

Alavi M, Spelman T, Matthews GV, Haber PS, Day C, van Beek I, Walsh N, Yeung B, Bruneau J, Petoumenos K, Dolan K, Kaldor JM, Dore GJ, Hellard M, Grebely J; ATAHC Study Group.

Int J Drug Policy. 2015 Oct;26(10):976-83. doi: 10.1016/j.drugpo.2015.05.003. Epub 2015 May 21.

7.

Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions.

Palmateer NE, Taylor A, Goldberg DJ, Munro A, Aitken C, Shepherd SJ, McAllister G, Gunson R, Hutchinson SJ.

PLoS One. 2014 Aug 11;9(8):e104515. doi: 10.1371/journal.pone.0104515. eCollection 2014.

8.

Impact of Hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: A systematic review.

Caven M, Malaguti A, Robinson E, Fletcher E, Dillon JF.

Int J Drug Policy. 2019 May 17. pii: S0955-3959(19)30133-1. doi: 10.1016/j.drugpo.2019.05.011. [Epub ahead of print]

PMID:
31109776
9.

Test uptake and hepatitis C prevalence in 5483 Danish people in drug use treatment from 1996 to 2015: a registry-based cohort study.

Øvrehus A, Nielsen S, Hansen JF, Holm DK, Christensen P.

Addiction. 2019 Mar;114(3):494-503. doi: 10.1111/add.14479. Epub 2018 Nov 25.

PMID:
30347471
10.

Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study.

Aspinall EJ, Weir A, Sacks-Davis R, Spelman T, Grebely J, Higgs P, Hutchinson SJ, Hellard ME.

Int J Drug Policy. 2014 Jan;25(1):179-82. doi: 10.1016/j.drugpo.2013.08.005. Epub 2013 Sep 8.

PMID:
24315504
11.

High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).

Wenz B, Nielsen S, Gassowski M, Santos-Hövener C, Cai W, Ross RS, Bock CT, Ratsch BA, Kücherer C, Bannert N, Bremer V, Hamouda O, Marcus U, Zimmermann R; DRUCK Study group.

BMC Public Health. 2016 Sep 5;16:927. doi: 10.1186/s12889-016-3545-4.

12.

Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings.

Vickerman P, Martin N, Turner K, Hickman M.

Addiction. 2012 Nov;107(11):1984-95. doi: 10.1111/j.1360-0443.2012.03932.x. Epub 2012 Jul 12.

PMID:
22564041
13.

Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study.

White B, Dore GJ, Lloyd AR, Rawlinson WD, Maher L.

Med J Aust. 2014 Sep 15;201(6):326-9.

PMID:
25222455
14.

A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs.

Spelman T, Morris MD, Zang G, Rice T, Page K, Maher L, Lloyd A, Grebely J, Dore GJ, Kim AY, Shoukry NH, Hellard M, Bruneau J; International Collaborative of Incident HIV and Hepatitis C in Injecting Cohorts (InC3 Study).

J Epidemiol Community Health. 2015 Aug;69(8):745-52. doi: 10.1136/jech-2014-205224. Epub 2015 Mar 26.

15.

Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.

MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, Taylor A, Roy K, Aspinall E, Goldberg D, Rhodes T, Hedrich D, Salminen M, Hickman M, Hutchinson SJ.

Int J Drug Policy. 2014 Jan;25(1):34-52. doi: 10.1016/j.drugpo.2013.07.001. Epub 2013 Aug 21. Review.

PMID:
23973009
16.

Understanding decisions made about hepatitis C treatment by couples who inject drugs.

Treloar C, Rance J, Bryant J, Fraser S.

J Viral Hepat. 2016 Feb;23(2):89-95. doi: 10.1111/jvh.12451. Epub 2015 Aug 25.

PMID:
26305873
17.

Hepatitis C testing and status among opioid substitution treatment clients in New South Wales.

Shand FL, Day C, Rawlinson W, Degenhardt L, Martin NG, Nelson EC.

Aust N Z J Public Health. 2014 Apr;38(2):160-4. doi: 10.1111/1753-6405.12173.

18.

HCV/HIV coinfection among people who inject drugs and enter opioid substitution treatment in Greece: prevalence and correlates.

Fotiou A, Kanavou E, Antaraki A, Richardson C, Terzidou M, Kokkevi A; Drug Related Infectious Diseases (DRID) Medical Doctors Group of OKANA.

Hepatol Med Policy. 2016 Aug 25;1:9. doi: 10.1186/s41124-016-0017-5. eCollection 2016.

19.

The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.

Butler K, Day C, Dietze P, Bruno R, Alati R, Burns L.

J Subst Abuse Treat. 2015 Nov;58:90-4. doi: 10.1016/j.jsat.2015.06.008. Epub 2015 Jun 17.

PMID:
26117080
20.

Injecting practices in sexual partnerships: hepatitis C transmission potentials in a 'risk equivalence' framework.

Harris M, Rhodes T.

Drug Alcohol Depend. 2013 Oct 1;132(3):617-23. doi: 10.1016/j.drugalcdep.2013.04.012. Epub 2013 May 7.

PMID:
23664125

Supplemental Content

Support Center